e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Airway inflammation and host defence
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Decreased levels of secretory leucoprotease inhibitor in the
pseudomonas
-infected cystic fibrosis lung are due to neutrophil elastase degradation
S. Weldon, P. McNally, N. G. McElvaney, S. Elborn, R. Levine, C. Taggart (Belfast, United Kingdom; Dublin, Ireland; Bethesda, United States Of America)
Source:
Annual Congress 2009 - Airway inflammation and host defence
Session:
Airway inflammation and host defence
Session type:
Thematic Poster Session
Number:
924
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Weldon, P. McNally, N. G. McElvaney, S. Elborn, R. Levine, C. Taggart (Belfast, United Kingdom; Dublin, Ireland; Bethesda, United States Of America). Decreased levels of secretory leucoprotease inhibitor in the
pseudomonas
-infected cystic fibrosis lung are due to neutrophil elastase degradation. Eur Respir J 2009; 34: Suppl. 53, 924
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
17β-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor
Source: Annual Congress 2010 - Epithelial cells: cell biology and role in lung disease
Year: 2010
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition
Source: Eur Respir J 2011; 37: 1083-1090
Year: 2011
Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis
Source: Eur Respir J 2015; 46: 384-394
Year: 2015
A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice
Source: Eur Respir J 2012; 40: 1475-1482
Year: 2012
Neutrophil elastase and lung damage in cystic fibrosis
Source: International Congress 2018 – Proteases: at the cutting edge of lung disease
Year: 2018
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema
Source: Eur Respir J 2002; 19: 1050-1057
Year: 2002
Inhibition of airway proteases in cystic fibrosis lung disease
Source: Eur Respir J 2008; 32: 783-795
Year: 2008
Neutrophilic inflammation predisposes to structural lung disease in cystic fibrosis (CF) via neutrophil elastase activity
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009
Neutrophil elastase is necessary for increases in active TGF-β in bleomycin-induced pulmonary fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 199s
Year: 2001
The role of matrix metalloproteinases in cystic fibrosis lung disease
Source: Eur Respir J 2011; 38: 721-727
Year: 2011
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase
Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases
Year: 2014
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Source: Eur Respir J 2007; 29: 240-250
Year: 2007
Decreased levels of elafin in the lungs of patients with acute lung injury as a result of proteolytic cleavage by the proteasome
Source: Annual Congress 2012 - Mechanistic studies in airway cell biology
Year: 2012
Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: Lung Science Conference 2015
Year: 2015
Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 586s
Year: 2002
Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases
Source: Eur Respir J 2003; 22: Suppl. 45, 83s
Year: 2003
Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis
Source: Eur Respir J, 51 (3) 1701910; 10.1183/13993003.01910-2017
Year: 2018
Targeting of cathepsin S reduces cystic fibrosis-like lung disease
Source: Eur Respir J, 53 (3) 1801523; 10.1183/13993003.01523-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept